ALN-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition Anna Borodovsky1; Kristina Yucius1; Andrew Sprague1; Nirmal K. Banda2; V. Michael Holers2; Akshay Vaishnaw1; Martin Maier1; Rajeev Kalla

First Page		Document Content
Date: 2014-12-06 10:10:48 RNA Small interfering RNA RNA interference C5-convertase Eculizumab C5 Complement component 5 Complement membrane attack complex Alternative complement pathway Complement system Biology Genetics		ALN-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition Anna Borodovsky1; Kristina Yucius1; Andrew Sprague1; Nirmal K. Banda2; V. Michael Holers2; Akshay Vaishnaw1; Martin Maier1; Rajeev Kalla Add to Reading List Source URL: www.alnylam.com Download Document from Source Website File Size: 877,47 KB Share Document on Facebook

	Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris DocID: 1pPKn - View Document
	HUS ParisMode de compatibilité] DocID: 1oXIv - View Document
	1 INTERIM FUNDING CRITERIA IN ONTARIO FOR SOLIRIS AHUS –CASE BY CASE BASIS Initiation Criteria A patient must meet all three of the following to obtain funding for initial treatment of eculizumab for aHUS: 1. Confirmed DocID: 19QJ8 - View Document
	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi DocID: 19nD4 - View Document
	PDF Document DocID: 16wNC - View Document